| Literature DB >> 26968790 |
Yayoi Matsumura-Kimoto1, Yoshihiro Inamoto2, Kinuko Tajima3, Akihisa Kawajiri3, Takashi Tanaka3, Tsuneaki Hirakawa3, Kazuko Ino3, Yu Asao3, Hiroyuki Tamogami3, Chika Kono3, Wataru Takeda3, Keiji Okinaka3, Shigeo Fuji3, Saiko Kurosawa3, Sung-Won Kim3, Ryuji Tanosaki4, Takuya Yamashita3, Takahiro Fukuda3.
Abstract
This study aimed to characterize the incidence and risk factors of invasive fungal disease, cytomegalovirus infection, other viral diseases, and gram-negative rod infection after glucocorticoid treatment for severe acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation and to elucidate the associations of cumulative steroid dose with the risks of individual infections. The study cohort included 91 consecutive patients who developed maximum grades III and IV acute GVHD at our center. The mean cumulative prednisolone-equivalent dose was 41 mg/kg during the first 4 weeks. The cumulative incidence rates of fungal disease, cytomegalovirus disease, other viral diseases, and gram-negative rod infection at 6 months after glucocorticoid treatment were remarkably high, at 14%, 21%, 28%, and 20%, respectively. GVHD within 26 days after transplantation and low lymphocyte count at GVHD treatment were associated with increased risks of several infections. Cumulative prednisolone-equivalent steroid doses ≥ 55 mg/kg during the first 4 weeks were associated with an increased risk of fungal disease (hazard ratio, 3.65; P = .03) and cumulative doses ≥ 23 mg/kg were associated with an increased risk of non-cytomegalovirus viral diseases (hazard ratio, 4.14; P = .02). Strategies to reduce the risk of infectious complications are needed, particularly for patients who have risk factors and those who receive high cumulative steroid doses.Entities:
Keywords: Adenovirus; Cytomegalovirus; Fungal infection; Graft-versus-host disease; Hematopoietic cell transplantation; Steroid dose
Mesh:
Substances:
Year: 2016 PMID: 26968790 DOI: 10.1016/j.bbmt.2016.02.020
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742